Anti-CD30-scFV-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cells

International Journal of Cancer

Volumn 110, Issue 3, 2004, Pages 386-394

  Heuser, Claudia ^a   Guhlke, Stefan ^b   Matthies, Alexander ^b   Bender, Hans ^b   Barth, Stefan ^c   Diehl, Volker ^a   Abken, Hinrich ^a   Hombach, Andreas ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c Fraunhofer Nuklear IME   (Germany)

Author keywords

Antibody cytokine fusion protein; IL 2 fusion protein; Immunotherapy; Recombinant antibodies; scFv

Indexed keywords

CD30 ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD30 INTERLEUKIN 2 FUSION PROTEIN; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CLONAL ANERGY; CONTROLLED STUDY; CYTOLYSIS; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; REED STERNBERG CELL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD30; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL SEPARATION; CYTOKINES; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HODGKIN DISEASE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTHERAPY; INTERLEUKIN-2; JURKAT CELLS; KILLER CELLS, NATURAL; LYMPHOCYTES; MICE; MICE, SCID; MICROSCOPY, FLUORESCENCE; MODELS, GENETIC; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TISSUE DISTRIBUTION;

EID: 2442528556     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20098     Document Type: Article

References (37)

1. Kadin ME. Pathology of Hodgkin's disease. Curr Opin Oncol 1994; 6:456-63.
2. Kuppers R, Rajewsky K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu Rev Immunol 1998;16:471-93.
3. Anagnostopoulos I, Hansmann ML, Franssila K, Harris M, Harris NL, Jaffe ES, Han J, van Krieken JM, Poppema S, Marafioti T, Franklin J, Sextro M, et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 2000;96:1889-99.
4. von Wasielewski R, Werner M, Fischer R, Hansmann ML, Hubner K, Hasenclever D, Franklin J, Sextro M, Diehl V, Georgii A. Lymphocyte-predominant Hodgkin's disease: an immunohistochemical analysis of 208 reviewed Hodgkin's disease cases from the German Hodgkin Study Group. Am J Pathol 1997;150:793-803.
5. Peh SC, Kim LH, Poppema S. TARC, a CC chemokine, is frequently expressed in classic Hodgkin's lymphoma but not in NLP Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and most cases of anaplastic large cell lymphoma. Am J Surg Pathol 2001;25:925-9.
6. Poppema S, van den Berg A. Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas. Semin Cancer Biol 2000;10:345-50.
7. van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. Am J Pathol 1999;154:1685-91.
8. Perussia B. Lymphokine-activated killer cells, natural killer cells and cytokines. Curr Opin Immunol 1991;3:49-55.
9. Hombach A, Muche JM, Gerken M, Gellrich S, Heuser C, Pohl C, Sterry W, Abken H. T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30(+) cutaneous lymphoma cells. Gene Ther 2001;8:891-5.
10. Hartmann F, Renner C, Jung W, Deisting C, Juwana M, Eichentopf B, Kloft M, Pfreundschuh M. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood 1997;89:2042-7.
11. Hombach A, Pohl C, Heuser C, Sircar R, Diehl V, Abken H. Isolation of single chain antibody fragments with specificity for cell surface antigens by phage display utilising internal image anti-idiotypic antibodies. J Immunol Methods 1998;218:53-61.
12. Engert A, Martin G, Pfreundschuh M, Amlot P, Hsu SM, Diehl V, Thorpe P. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumours in mice. Cancer Res 1990;50:2929-35.
13. Pohl C, Renner C, Schwonzen M, Schobert I, Liebenberg V, Jung W, Wolf J, Pfreundschuh M, Diehl V. CD30-specific AB1-AB2-AB3 internal image antibody network: potential use as anti-idiotype vaccine against Hodgkin's lymphoma. Int J Cancer 1993;54:418-25.
14. Renner C, Jung W, Sahin U, van Lier R, Pfreundschuh M. The role of lymphocyte subsets and adhesion molecules in T cell-dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies. Eur J Immunol 1995;25:2027-33.
15. Wolf J, Kapp U, Bohlen H, Kornacker M, Schoch C, Stahl B, Mucke S, von Kalle C, Fonatsch C, Schaefer HE, Hansmann ML, Diehl V. Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. Blood 1996;87:3418-28.
16. Diehl V, Burrichter H, Schaadt M, Kirchner HH, Fonatsch C, Stein H, Gerdes J, Heit W, Ziegler A. Hodgkin's disease cell lines: characteristics and biological activities. Hamatol Bluttransfus 1983;28:411-7.
17. Shu L, Qi CF, Schlom J, Kashmiri SV. Secretion of a single-gene-encoded immunoglobulin from myeloma cells. Proc Natl Acad Sci U S A 1993;90:7995-9.
18. Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, Pohl C, Abken H. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. Cancer Res 1998;58:1116-9.
19. Jost LM, Kirkwood JM, Whiteside TL. Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumour cells. J Immunol Methods 1992;147:153-65.
20. Kanzler H, Hansmann ML, Kapp U, Wolf J, Diehl V, Rajewsky K, Kuppers R. Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient. Blood 1996; 87:3429-36.
21. Maggio E, van den Berg A, Diepstra A, Kluiver J, Kluiver J, Visser L, Poppema S. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol 2002;13:52-6.
22. Willenbrock K, Roers A, Blohbaum B, Rajewsky K, Hansmann ML. CD8(+) T cells in Hodgkin's disease tumour tissue are a polyclonal population with limited clonal expansion but little evidence of selection by antigen. Am J Pathol 2000;157:171-5.
23. Riccobene TA, Miceli RC, Lincoln C, Knight Y, Meadows J, Stabin MG, Sung C. Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumours in mice. J Nucl Med 2003;44:422-33.
24. Josting A, Diehl V. Current treatment strategies in early stage Hodgkin's disease. Curr Treat Options Oncol 2003;4:297-305.
25. Josting A, Engert A, Diehl V, Canellos GP. Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin's disease. Ann Oncol 2002;13:112-6.
26. Oudejans JJ, Jiwa NM, Kummer JA, Ossenkoppele GJ, van Heerde P, Baars JW, Kluin PM, Kluin-Nelemans JC, van Diest PJ, Middeldorp JM, Meijer CJ. Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood 1997;89:1376-82.
27. + T lymphocytes. Int J Cancer 1995;62:5-10.
28. Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN, Vickers MA. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2003;XX:XX-XX.
29. Sabzevari H, Gillies SD, Mueller BM, Pancook JD, Reisfeld RA. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci U S A 1994;91:9626-30.
30. Becker JC, Pancook JD, Gillies SD, Furukawa K, Reisfeld RA. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 1996;183:2361-6.
31. Lode HN, Xiang R, Dreier T, Varki NM, Gillies SD, Reisfeld RA. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 1998;91: 1706-15.
32. Matsumoto H, Liao S, Arakawa F, Ueno A, Abe H, Awasthi A, Kuroki M. Targeting of interleukin-2 to human MK-1-expressing carcinoma by fusion with a single-chain Fv of anti-MK-1 antibody. Anticancer Res 2002;22:2001-7.
33. Wang B, Xiong Q, Shi Q, Le X, Xie K. Genetic disruption of host interferon-gamma drastically enhances the metastasis of pancreatic adenocarcinoma through impaired expression of inducible nitric oxide synthase. Oncogene 2001;20:6930-7.
34. Kemp RA, Ronchese F. Tumour-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J Immunol 2001;167:6497-502.
35. McGuirk P, Mills K. Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. Trends Immunol 2002;23:450.
36. Hombach A, Jung W, Pohl C, Renner C, Sahin U, Schmits R, Wolf J, Kapp U, Diehl V, Pfreundschuh M. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo. Int J Cancer 1993;55:830-6.
37. Hartmann F, Renner C, Jung W, da Costa L, Tembrink S, Held G, Sek A, Konig J, Bauer S, Kloft M, Pfreundschuh M. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res 2001;7: 1873-81.